logo-loader
viewPolarean Imaging PLC

Polarean adds third trial site to late-stage study of its lung MRI scan technology

MRI scans generally aren’t very useful in assessing lung function, but Polarean’s 129Xe gas is trying to change that

lung
The commercial launch of Polarean’s drug-device combo remains on track for the second half of 2020

Polarean Imaging Plc (LON:POLX) is adding a third clinical trial site to the phase III study of its hyperpolarised 129-Xenon (129Xe) gas magnetic resonance imaging (MRI) technology.

MRI scans generally aren't much use when assessing lung function, but Polarean has developed a way in which a small amount of inert gas can change that.

READ: Polarean Imaging appoints former CFO of cancer therapeutics firm as new finance boss

By inhaling and holding a small amount of the 129Xe gas for just a few seconds, the patient is able to create a much stronger MRI signal, providing doctors with multiple images of lung structure and function.

Polarean, which is looking to sell the gas, the instrument which polarises the gas, and an associated quality assurance device, kicked off a trial of the technology last summer in two sites: Duke University and the University of Virginia.

Enrolment for the trials has now passed 80% (39 of 48 patients) in the lung transplant pathway and 50% (16 of 32) in the lung resection pathway.

Third site added

To improve the rate of enrolment for the lung resection pathway in order to align the pathway completion dates, and because neither site should enrol more than 65% of patients in a pathway, Polarean plans to add a third trial site at the University of Cincinnati, which is already one of its key clinical collaborators.

It is expected that UC will start enrolling patients next month (June), and bosses are confident it will not affect the regulatory submission timetable, with commercial launch still being targeted for the second half of 2020.

Boss content

“We are satisfied with the progress of our clinical trials to date,” said chief executive Richard Hullihen.

“We are pleased to be adding an additional trial site at UC to improve the enrolment process for the lung resection pathway, thereby extending our collaboration with UC.”

Quick facts: Polarean Imaging PLC

Price: 19 GBX

AIM:POLX
Market: AIM
Market Cap: £21.74 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Polarean Imaging PLC named herein, including the promotion by the Company of Polarean Imaging PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Polarean Imaging eagerly awaiting readouts from its key phase III clinical...

Polarean Imaging PLC's (LON:POLX) Richard Hullihen speaks to Proactive London's Andrew Scott following the news they've now completed patient enrolment for the phase III clinical trials of its MRI lung scan technology. He says the trials are now in the image and statistical analysis stage, a...

6 days, 12 hours ago

2 min read